DaVita HealthCare Partners (NYSE:DVA) was upgraded by research analysts at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Thursday.

A number of other brokerages have also issued reports on DVA. Royal Bank Of Canada reissued a “hold” rating and issued a $64.00 target price on shares of DaVita HealthCare Partners in a research report on Wednesday, September 6th. J P Morgan Chase & Co lowered DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a research report on Monday, October 9th. Robert W. Baird reissued a “hold” rating and issued a $63.00 target price on shares of DaVita HealthCare Partners in a research report on Friday, November 10th. SunTrust Banks set a $57.00 target price on DaVita HealthCare Partners and gave the company a “hold” rating in a research report on Sunday, October 15th. Finally, KeyCorp reissued a “hold” rating on shares of DaVita HealthCare Partners in a research report on Monday, November 13th. Four investment analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. DaVita HealthCare Partners has an average rating of “Hold” and a consensus target price of $63.00.

Shares of DaVita HealthCare Partners (DVA) opened at $69.20 on Thursday. The company has a market cap of $11,529.89, a P/E ratio of 17.41, a PEG ratio of 12.28 and a beta of 0.97. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. DaVita HealthCare Partners has a 12-month low of $52.51 and a 12-month high of $70.16.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). The firm had revenue of $3.92 billion for the quarter, compared to analysts’ expectations of $3.91 billion. DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.95 EPS. analysts forecast that DaVita HealthCare Partners will post 3.42 earnings per share for the current year.

DaVita HealthCare Partners announced that its board has authorized a share repurchase program on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in outstanding shares. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Several institutional investors have recently bought and sold shares of the company. California Public Employees Retirement System increased its position in shares of DaVita HealthCare Partners by 1.9% during the third quarter. California Public Employees Retirement System now owns 490,132 shares of the company’s stock worth $29,109,000 after acquiring an additional 9,332 shares during the period. Canada Pension Plan Investment Board increased its position in shares of DaVita HealthCare Partners by 14.7% during the third quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock worth $26,390,000 after acquiring an additional 56,988 shares during the period. Schroder Investment Management Group increased its position in shares of DaVita HealthCare Partners by 769.0% during the third quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock worth $25,387,000 after acquiring an additional 384,224 shares during the period. Speece Thorson Capital Group Inc. increased its position in shares of DaVita HealthCare Partners by 14.5% during the third quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock worth $19,075,000 after acquiring an additional 40,667 shares during the period. Finally, Rhumbline Advisers increased its position in shares of DaVita HealthCare Partners by 4.4% during the third quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock worth $19,073,000 after acquiring an additional 13,471 shares during the period. 85.32% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/07/davita-healthcare-partners-dva-upgraded-at-raymond-james-financial.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.